Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare
Free Samples
Cardiovascular

PUBLISHER: Global Industry Analysts, Inc. | PRODUCT CODE: 1536108

Cover Image

PUBLISHER: Global Industry Analysts, Inc. | PRODUCT CODE: 1536108

Thrombosis Drugs

PUBLISHED:
PAGES: 387 Pages
DELIVERY TIME: 1-2 business days
REQUEST FREE SAMPLE
REQUEST CUSTOMIZATION
SELECT AN OPTION
PDF (Single User License)
USD 5450
PDF (Global License to Company and its Fully-owned Subsidiaries)
USD 16350

Add to Cart

Description

Table of Contents

Global Thrombosis Drugs Market to Reach US$53.9 Billion by 2030

The global market for Thrombosis Drugs estimated at US$32.0 Billion in the year 2023, is expected to reach US$53.9 Billion by 2030, growing at a CAGR of 7.7% over the analysis period 2023-2030. Venous Thromboembolism Drugs, one of the segments analyzed in the report, is expected to record a 9.0% CAGR and reach US$23.7 Billion by the end of the analysis period. Growth in the Deep Vein Thrombosis Drugs segment is estimated at 7.3% CAGR over the analysis period.

The U.S. Market is Estimated at US$8.7 Billion While China is Forecast to Grow at 12.5% CAGR

The Thrombosis Drugs market in the U.S. is estimated at US$8.7 Billion in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$12.2 Billion by the year 2030 trailing a CAGR of 12.5% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 3.3% and 7.6% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 5.0% CAGR.

Global Thrombosis Drugs Market - Key Trends and Drivers Summarized

Thrombosis drugs are pharmaceutical agents used to prevent and treat thrombosis, which is the formation of a blood clot inside a blood vessel, potentially obstructing the flow of blood through the circulatory system. These drugs play a critical role in managing conditions such as deep vein thrombosis (DVT), pulmonary embolism (PE), and stroke, which are significant causes of morbidity and mortality worldwide. The main classes of thrombosis drugs include anticoagulants like warfarin and newer direct oral anticoagulants (DOACs) such as dabigatran and rivaroxaban, antiplatelets like aspirin and clopidogrel, and thrombolytics used to dissolve clots. Anticoagulants work by interrupting the process that leads to clot formation, while antiplatelets prevent platelets from clumping together to form a clot, and thrombolytics help dissolve clots that have already formed. The choice of drug often depends on the specific thrombotic risk, patient factors, and the balance between reducing clotting risk and increasing the risk of bleeding, which is a common side effect of these medications.

The field of thrombosis drugs has seen significant advancements over the past few years, primarily driven by the development of DOACs, which offer several benefits over traditional warfarin therapy, including fewer dietary restrictions, reduced need for monitoring, and a lower risk of certain types of bleeding. These new agents have dramatically changed the landscape of anticoagulation therapy, providing more options and flexibility for both patients and healthcare providers. Furthermore, ongoing research continues to focus on developing safer, more effective thrombosis drugs with quicker onset actions and reversible effects to manage and mitigate the risks associated with emergency situations. Another important area of development is the personalization of thrombosis treatment based on genetic profiles, which can predict responses to certain drugs and help tailor treatments to individual needs, thereby maximizing efficacy and minimizing risks.

The growth in the thrombosis drugs market is driven by several factors, including an aging global population, increasing prevalence of cardiovascular diseases and conditions requiring thrombosis management, and technological advancements in drug development and personalization. The aging demographic is particularly prone to thrombotic events, which naturally increases the demand for effective thrombosis treatments. As cardiovascular conditions rise globally due to lifestyle factors and increased longevity, the need for effective clot management strategies becomes more critical. Furthermore, advancements in pharmacology and drug delivery systems, such as the development of targeted and timed-release drug formulations, enhance the effectiveness and user compliance of these treatments. The growing awareness of the risks associated with thrombosis and the availability of new treatment options have also encouraged more proactive management of potential thrombotic conditions. Lastly, healthcare systems are increasingly adopting guidelines that favor the early introduction and sustained use of thrombosis drugs in at-risk populations, supported by evidence-based practices. These trends collectively fuel the expansion of the thrombosis drugs market, reflecting ongoing efforts to improve patient outcomes in thrombosis management.

Select Competitors (Total 86 Featured) -

  • Aspen Global Inc.
  • Bayer AG
  • Biogen, Inc.
  • Boehringer Ingelheim International GmbH
  • Bristol-Myers Squibb Company
  • CSL Ltd.
  • Daiichi Sankyo Co., Ltd.
  • Eugia US LLC
  • Grifols International SA
  • Italfarmaco SpA
  • LEO Pharma A/S
  • Merck & Co., Inc.
  • Regeneron Pharmaceuticals, Inc.
  • Sanofi SA
  • Viatris;
Show more
Product Code: MCP26637

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Global Economic Update
    • Thrombosis Drugs - Global Key Competitors Percentage Market Share in 2024 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Prevalence of Thrombotic Disorders Drives Market Growth
    • Advances in Anticoagulant Therapy Propel Market Demand
    • Expansion of Cardiovascular Disease Management Spurs Market Adoption
    • Growing Awareness of Thrombosis and Its Complications Expands Addressable Market Opportunity
    • Rising Demand for Novel Oral Anticoagulants (NOACs) Drives Market Dynamics
    • Increasing Adoption in Hospital and Ambulatory Care Settings Propels Market Growth
    • Expansion of Health Insurance Coverage Strengthens Market Adoption
    • Growing Trend of Home-Based and Long-Term Care Bodes Well for Market Expansion
    • Increasing Availability of Generic and Biosimilar Drugs Strengthens Market Dynamics
    • Growth of the Aging Population Sets the Stage for Market Expansion
    • Increasing Use of Combination Therapies Generates New Opportunities
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Thrombosis Drugs Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Thrombosis Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Thrombosis Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 4: World 16-Year Perspective for Thrombosis Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2024 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Venous Thromboembolism by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Venous Thromboembolism by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 7: World 16-Year Perspective for Venous Thromboembolism by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Deep Vein Thrombosis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Deep Vein Thrombosis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 10: World 16-Year Perspective for Deep Vein Thrombosis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Pulmonary Embolism by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Pulmonary Embolism by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 13: World 16-Year Perspective for Pulmonary Embolism by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Other Disease Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Other Disease Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 16: World 16-Year Perspective for Other Disease Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Online Distribution Channel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Online Distribution Channel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 19: World 16-Year Perspective for Online Distribution Channel by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 22: World 16-Year Perspective for Hospital Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 25: World 16-Year Perspective for Retail Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Anticoagulants by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Anticoagulants by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 28: World 16-Year Perspective for Anticoagulants by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 29: World Recent Past, Current & Future Analysis for Antiplatelet Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 30: World Historic Review for Antiplatelet Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 31: World 16-Year Perspective for Antiplatelet Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 32: World Recent Past, Current & Future Analysis for Thrombolytic Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 33: World Historic Review for Thrombolytic Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 34: World 16-Year Perspective for Thrombolytic Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Thrombosis Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
    • TABLE 35: USA Recent Past, Current & Future Analysis for Thrombosis Drugs by Disease Type - Venous Thromboembolism, Deep Vein Thrombosis, Pulmonary Embolism and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 36: USA Historic Review for Thrombosis Drugs by Disease Type - Venous Thromboembolism, Deep Vein Thrombosis, Pulmonary Embolism and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 37: USA 16-Year Perspective for Thrombosis Drugs by Disease Type - Percentage Breakdown of Value Sales for Venous Thromboembolism, Deep Vein Thrombosis, Pulmonary Embolism and Other Disease Types for the Years 2014, 2024 & 2030
    • TABLE 38: USA Recent Past, Current & Future Analysis for Thrombosis Drugs by Distribution Channel - Online Distribution Channel, Hospital Pharmacies and Retail Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 39: USA Historic Review for Thrombosis Drugs by Distribution Channel - Online Distribution Channel, Hospital Pharmacies and Retail Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 40: USA 16-Year Perspective for Thrombosis Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Online Distribution Channel, Hospital Pharmacies and Retail Pharmacies for the Years 2014, 2024 & 2030
    • TABLE 41: USA Recent Past, Current & Future Analysis for Thrombosis Drugs by Drug Class - Anticoagulants, Antiplatelet Drugs and Thrombolytic Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 42: USA Historic Review for Thrombosis Drugs by Drug Class - Anticoagulants, Antiplatelet Drugs and Thrombolytic Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 43: USA 16-Year Perspective for Thrombosis Drugs by Drug Class - Percentage Breakdown of Value Sales for Anticoagulants, Antiplatelet Drugs and Thrombolytic Drugs for the Years 2014, 2024 & 2030
  • CANADA
    • TABLE 44: Canada Recent Past, Current & Future Analysis for Thrombosis Drugs by Disease Type - Venous Thromboembolism, Deep Vein Thrombosis, Pulmonary Embolism and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 45: Canada Historic Review for Thrombosis Drugs by Disease Type - Venous Thromboembolism, Deep Vein Thrombosis, Pulmonary Embolism and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 46: Canada 16-Year Perspective for Thrombosis Drugs by Disease Type - Percentage Breakdown of Value Sales for Venous Thromboembolism, Deep Vein Thrombosis, Pulmonary Embolism and Other Disease Types for the Years 2014, 2024 & 2030
    • TABLE 47: Canada Recent Past, Current & Future Analysis for Thrombosis Drugs by Distribution Channel - Online Distribution Channel, Hospital Pharmacies and Retail Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 48: Canada Historic Review for Thrombosis Drugs by Distribution Channel - Online Distribution Channel, Hospital Pharmacies and Retail Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 49: Canada 16-Year Perspective for Thrombosis Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Online Distribution Channel, Hospital Pharmacies and Retail Pharmacies for the Years 2014, 2024 & 2030
    • TABLE 50: Canada Recent Past, Current & Future Analysis for Thrombosis Drugs by Drug Class - Anticoagulants, Antiplatelet Drugs and Thrombolytic Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 51: Canada Historic Review for Thrombosis Drugs by Drug Class - Anticoagulants, Antiplatelet Drugs and Thrombolytic Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 52: Canada 16-Year Perspective for Thrombosis Drugs by Drug Class - Percentage Breakdown of Value Sales for Anticoagulants, Antiplatelet Drugs and Thrombolytic Drugs for the Years 2014, 2024 & 2030
  • JAPAN
    • Thrombosis Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
    • TABLE 53: Japan Recent Past, Current & Future Analysis for Thrombosis Drugs by Disease Type - Venous Thromboembolism, Deep Vein Thrombosis, Pulmonary Embolism and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 54: Japan Historic Review for Thrombosis Drugs by Disease Type - Venous Thromboembolism, Deep Vein Thrombosis, Pulmonary Embolism and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 55: Japan 16-Year Perspective for Thrombosis Drugs by Disease Type - Percentage Breakdown of Value Sales for Venous Thromboembolism, Deep Vein Thrombosis, Pulmonary Embolism and Other Disease Types for the Years 2014, 2024 & 2030
    • TABLE 56: Japan Recent Past, Current & Future Analysis for Thrombosis Drugs by Distribution Channel - Online Distribution Channel, Hospital Pharmacies and Retail Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 57: Japan Historic Review for Thrombosis Drugs by Distribution Channel - Online Distribution Channel, Hospital Pharmacies and Retail Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 58: Japan 16-Year Perspective for Thrombosis Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Online Distribution Channel, Hospital Pharmacies and Retail Pharmacies for the Years 2014, 2024 & 2030
    • TABLE 59: Japan Recent Past, Current & Future Analysis for Thrombosis Drugs by Drug Class - Anticoagulants, Antiplatelet Drugs and Thrombolytic Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 60: Japan Historic Review for Thrombosis Drugs by Drug Class - Anticoagulants, Antiplatelet Drugs and Thrombolytic Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 61: Japan 16-Year Perspective for Thrombosis Drugs by Drug Class - Percentage Breakdown of Value Sales for Anticoagulants, Antiplatelet Drugs and Thrombolytic Drugs for the Years 2014, 2024 & 2030
  • CHINA
    • Thrombosis Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
    • TABLE 62: China Recent Past, Current & Future Analysis for Thrombosis Drugs by Disease Type - Venous Thromboembolism, Deep Vein Thrombosis, Pulmonary Embolism and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 63: China Historic Review for Thrombosis Drugs by Disease Type - Venous Thromboembolism, Deep Vein Thrombosis, Pulmonary Embolism and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 64: China 16-Year Perspective for Thrombosis Drugs by Disease Type - Percentage Breakdown of Value Sales for Venous Thromboembolism, Deep Vein Thrombosis, Pulmonary Embolism and Other Disease Types for the Years 2014, 2024 & 2030
    • TABLE 65: China Recent Past, Current & Future Analysis for Thrombosis Drugs by Distribution Channel - Online Distribution Channel, Hospital Pharmacies and Retail Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 66: China Historic Review for Thrombosis Drugs by Distribution Channel - Online Distribution Channel, Hospital Pharmacies and Retail Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 67: China 16-Year Perspective for Thrombosis Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Online Distribution Channel, Hospital Pharmacies and Retail Pharmacies for the Years 2014, 2024 & 2030
    • TABLE 68: China Recent Past, Current & Future Analysis for Thrombosis Drugs by Drug Class - Anticoagulants, Antiplatelet Drugs and Thrombolytic Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 69: China Historic Review for Thrombosis Drugs by Drug Class - Anticoagulants, Antiplatelet Drugs and Thrombolytic Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 70: China 16-Year Perspective for Thrombosis Drugs by Drug Class - Percentage Breakdown of Value Sales for Anticoagulants, Antiplatelet Drugs and Thrombolytic Drugs for the Years 2014, 2024 & 2030
  • EUROPE
    • Thrombosis Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
    • TABLE 71: Europe Recent Past, Current & Future Analysis for Thrombosis Drugs by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 72: Europe Historic Review for Thrombosis Drugs by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 73: Europe 16-Year Perspective for Thrombosis Drugs by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2024 & 2030
    • TABLE 74: Europe Recent Past, Current & Future Analysis for Thrombosis Drugs by Disease Type - Venous Thromboembolism, Deep Vein Thrombosis, Pulmonary Embolism and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 75: Europe Historic Review for Thrombosis Drugs by Disease Type - Venous Thromboembolism, Deep Vein Thrombosis, Pulmonary Embolism and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 76: Europe 16-Year Perspective for Thrombosis Drugs by Disease Type - Percentage Breakdown of Value Sales for Venous Thromboembolism, Deep Vein Thrombosis, Pulmonary Embolism and Other Disease Types for the Years 2014, 2024 & 2030
    • TABLE 77: Europe Recent Past, Current & Future Analysis for Thrombosis Drugs by Distribution Channel - Online Distribution Channel, Hospital Pharmacies and Retail Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 78: Europe Historic Review for Thrombosis Drugs by Distribution Channel - Online Distribution Channel, Hospital Pharmacies and Retail Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 79: Europe 16-Year Perspective for Thrombosis Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Online Distribution Channel, Hospital Pharmacies and Retail Pharmacies for the Years 2014, 2024 & 2030
    • TABLE 80: Europe Recent Past, Current & Future Analysis for Thrombosis Drugs by Drug Class - Anticoagulants, Antiplatelet Drugs and Thrombolytic Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 81: Europe Historic Review for Thrombosis Drugs by Drug Class - Anticoagulants, Antiplatelet Drugs and Thrombolytic Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 82: Europe 16-Year Perspective for Thrombosis Drugs by Drug Class - Percentage Breakdown of Value Sales for Anticoagulants, Antiplatelet Drugs and Thrombolytic Drugs for the Years 2014, 2024 & 2030
  • FRANCE
    • Thrombosis Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
    • TABLE 83: France Recent Past, Current & Future Analysis for Thrombosis Drugs by Disease Type - Venous Thromboembolism, Deep Vein Thrombosis, Pulmonary Embolism and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 84: France Historic Review for Thrombosis Drugs by Disease Type - Venous Thromboembolism, Deep Vein Thrombosis, Pulmonary Embolism and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 85: France 16-Year Perspective for Thrombosis Drugs by Disease Type - Percentage Breakdown of Value Sales for Venous Thromboembolism, Deep Vein Thrombosis, Pulmonary Embolism and Other Disease Types for the Years 2014, 2024 & 2030
    • TABLE 86: France Recent Past, Current & Future Analysis for Thrombosis Drugs by Distribution Channel - Online Distribution Channel, Hospital Pharmacies and Retail Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 87: France Historic Review for Thrombosis Drugs by Distribution Channel - Online Distribution Channel, Hospital Pharmacies and Retail Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 88: France 16-Year Perspective for Thrombosis Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Online Distribution Channel, Hospital Pharmacies and Retail Pharmacies for the Years 2014, 2024 & 2030
    • TABLE 89: France Recent Past, Current & Future Analysis for Thrombosis Drugs by Drug Class - Anticoagulants, Antiplatelet Drugs and Thrombolytic Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 90: France Historic Review for Thrombosis Drugs by Drug Class - Anticoagulants, Antiplatelet Drugs and Thrombolytic Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 91: France 16-Year Perspective for Thrombosis Drugs by Drug Class - Percentage Breakdown of Value Sales for Anticoagulants, Antiplatelet Drugs and Thrombolytic Drugs for the Years 2014, 2024 & 2030
  • GERMANY
    • Thrombosis Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
    • TABLE 92: Germany Recent Past, Current & Future Analysis for Thrombosis Drugs by Disease Type - Venous Thromboembolism, Deep Vein Thrombosis, Pulmonary Embolism and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 93: Germany Historic Review for Thrombosis Drugs by Disease Type - Venous Thromboembolism, Deep Vein Thrombosis, Pulmonary Embolism and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 94: Germany 16-Year Perspective for Thrombosis Drugs by Disease Type - Percentage Breakdown of Value Sales for Venous Thromboembolism, Deep Vein Thrombosis, Pulmonary Embolism and Other Disease Types for the Years 2014, 2024 & 2030
    • TABLE 95: Germany Recent Past, Current & Future Analysis for Thrombosis Drugs by Distribution Channel - Online Distribution Channel, Hospital Pharmacies and Retail Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 96: Germany Historic Review for Thrombosis Drugs by Distribution Channel - Online Distribution Channel, Hospital Pharmacies and Retail Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 97: Germany 16-Year Perspective for Thrombosis Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Online Distribution Channel, Hospital Pharmacies and Retail Pharmacies for the Years 2014, 2024 & 2030
    • TABLE 98: Germany Recent Past, Current & Future Analysis for Thrombosis Drugs by Drug Class - Anticoagulants, Antiplatelet Drugs and Thrombolytic Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 99: Germany Historic Review for Thrombosis Drugs by Drug Class - Anticoagulants, Antiplatelet Drugs and Thrombolytic Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 100: Germany 16-Year Perspective for Thrombosis Drugs by Drug Class - Percentage Breakdown of Value Sales for Anticoagulants, Antiplatelet Drugs and Thrombolytic Drugs for the Years 2014, 2024 & 2030
  • ITALY
    • TABLE 101: Italy Recent Past, Current & Future Analysis for Thrombosis Drugs by Disease Type - Venous Thromboembolism, Deep Vein Thrombosis, Pulmonary Embolism and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 102: Italy Historic Review for Thrombosis Drugs by Disease Type - Venous Thromboembolism, Deep Vein Thrombosis, Pulmonary Embolism and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 103: Italy 16-Year Perspective for Thrombosis Drugs by Disease Type - Percentage Breakdown of Value Sales for Venous Thromboembolism, Deep Vein Thrombosis, Pulmonary Embolism and Other Disease Types for the Years 2014, 2024 & 2030
    • TABLE 104: Italy Recent Past, Current & Future Analysis for Thrombosis Drugs by Distribution Channel - Online Distribution Channel, Hospital Pharmacies and Retail Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 105: Italy Historic Review for Thrombosis Drugs by Distribution Channel - Online Distribution Channel, Hospital Pharmacies and Retail Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 106: Italy 16-Year Perspective for Thrombosis Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Online Distribution Channel, Hospital Pharmacies and Retail Pharmacies for the Years 2014, 2024 & 2030
    • TABLE 107: Italy Recent Past, Current & Future Analysis for Thrombosis Drugs by Drug Class - Anticoagulants, Antiplatelet Drugs and Thrombolytic Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 108: Italy Historic Review for Thrombosis Drugs by Drug Class - Anticoagulants, Antiplatelet Drugs and Thrombolytic Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 109: Italy 16-Year Perspective for Thrombosis Drugs by Drug Class - Percentage Breakdown of Value Sales for Anticoagulants, Antiplatelet Drugs and Thrombolytic Drugs for the Years 2014, 2024 & 2030
  • UNITED KINGDOM
    • Thrombosis Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
    • TABLE 110: UK Recent Past, Current & Future Analysis for Thrombosis Drugs by Disease Type - Venous Thromboembolism, Deep Vein Thrombosis, Pulmonary Embolism and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 111: UK Historic Review for Thrombosis Drugs by Disease Type - Venous Thromboembolism, Deep Vein Thrombosis, Pulmonary Embolism and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 112: UK 16-Year Perspective for Thrombosis Drugs by Disease Type - Percentage Breakdown of Value Sales for Venous Thromboembolism, Deep Vein Thrombosis, Pulmonary Embolism and Other Disease Types for the Years 2014, 2024 & 2030
    • TABLE 113: UK Recent Past, Current & Future Analysis for Thrombosis Drugs by Distribution Channel - Online Distribution Channel, Hospital Pharmacies and Retail Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 114: UK Historic Review for Thrombosis Drugs by Distribution Channel - Online Distribution Channel, Hospital Pharmacies and Retail Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 115: UK 16-Year Perspective for Thrombosis Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Online Distribution Channel, Hospital Pharmacies and Retail Pharmacies for the Years 2014, 2024 & 2030
    • TABLE 116: UK Recent Past, Current & Future Analysis for Thrombosis Drugs by Drug Class - Anticoagulants, Antiplatelet Drugs and Thrombolytic Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 117: UK Historic Review for Thrombosis Drugs by Drug Class - Anticoagulants, Antiplatelet Drugs and Thrombolytic Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 118: UK 16-Year Perspective for Thrombosis Drugs by Drug Class - Percentage Breakdown of Value Sales for Anticoagulants, Antiplatelet Drugs and Thrombolytic Drugs for the Years 2014, 2024 & 2030
  • SPAIN
    • TABLE 119: Spain Recent Past, Current & Future Analysis for Thrombosis Drugs by Disease Type - Venous Thromboembolism, Deep Vein Thrombosis, Pulmonary Embolism and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 120: Spain Historic Review for Thrombosis Drugs by Disease Type - Venous Thromboembolism, Deep Vein Thrombosis, Pulmonary Embolism and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 121: Spain 16-Year Perspective for Thrombosis Drugs by Disease Type - Percentage Breakdown of Value Sales for Venous Thromboembolism, Deep Vein Thrombosis, Pulmonary Embolism and Other Disease Types for the Years 2014, 2024 & 2030
    • TABLE 122: Spain Recent Past, Current & Future Analysis for Thrombosis Drugs by Distribution Channel - Online Distribution Channel, Hospital Pharmacies and Retail Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 123: Spain Historic Review for Thrombosis Drugs by Distribution Channel - Online Distribution Channel, Hospital Pharmacies and Retail Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 124: Spain 16-Year Perspective for Thrombosis Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Online Distribution Channel, Hospital Pharmacies and Retail Pharmacies for the Years 2014, 2024 & 2030
    • TABLE 125: Spain Recent Past, Current & Future Analysis for Thrombosis Drugs by Drug Class - Anticoagulants, Antiplatelet Drugs and Thrombolytic Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 126: Spain Historic Review for Thrombosis Drugs by Drug Class - Anticoagulants, Antiplatelet Drugs and Thrombolytic Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 127: Spain 16-Year Perspective for Thrombosis Drugs by Drug Class - Percentage Breakdown of Value Sales for Anticoagulants, Antiplatelet Drugs and Thrombolytic Drugs for the Years 2014, 2024 & 2030
  • RUSSIA
    • TABLE 128: Russia Recent Past, Current & Future Analysis for Thrombosis Drugs by Disease Type - Venous Thromboembolism, Deep Vein Thrombosis, Pulmonary Embolism and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 129: Russia Historic Review for Thrombosis Drugs by Disease Type - Venous Thromboembolism, Deep Vein Thrombosis, Pulmonary Embolism and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 130: Russia 16-Year Perspective for Thrombosis Drugs by Disease Type - Percentage Breakdown of Value Sales for Venous Thromboembolism, Deep Vein Thrombosis, Pulmonary Embolism and Other Disease Types for the Years 2014, 2024 & 2030
    • TABLE 131: Russia Recent Past, Current & Future Analysis for Thrombosis Drugs by Distribution Channel - Online Distribution Channel, Hospital Pharmacies and Retail Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 132: Russia Historic Review for Thrombosis Drugs by Distribution Channel - Online Distribution Channel, Hospital Pharmacies and Retail Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 133: Russia 16-Year Perspective for Thrombosis Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Online Distribution Channel, Hospital Pharmacies and Retail Pharmacies for the Years 2014, 2024 & 2030
    • TABLE 134: Russia Recent Past, Current & Future Analysis for Thrombosis Drugs by Drug Class - Anticoagulants, Antiplatelet Drugs and Thrombolytic Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 135: Russia Historic Review for Thrombosis Drugs by Drug Class - Anticoagulants, Antiplatelet Drugs and Thrombolytic Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 136: Russia 16-Year Perspective for Thrombosis Drugs by Drug Class - Percentage Breakdown of Value Sales for Anticoagulants, Antiplatelet Drugs and Thrombolytic Drugs for the Years 2014, 2024 & 2030
  • REST OF EUROPE
    • TABLE 137: Rest of Europe Recent Past, Current & Future Analysis for Thrombosis Drugs by Disease Type - Venous Thromboembolism, Deep Vein Thrombosis, Pulmonary Embolism and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 138: Rest of Europe Historic Review for Thrombosis Drugs by Disease Type - Venous Thromboembolism, Deep Vein Thrombosis, Pulmonary Embolism and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 139: Rest of Europe 16-Year Perspective for Thrombosis Drugs by Disease Type - Percentage Breakdown of Value Sales for Venous Thromboembolism, Deep Vein Thrombosis, Pulmonary Embolism and Other Disease Types for the Years 2014, 2024 & 2030
    • TABLE 140: Rest of Europe Recent Past, Current & Future Analysis for Thrombosis Drugs by Distribution Channel - Online Distribution Channel, Hospital Pharmacies and Retail Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 141: Rest of Europe Historic Review for Thrombosis Drugs by Distribution Channel - Online Distribution Channel, Hospital Pharmacies and Retail Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 142: Rest of Europe 16-Year Perspective for Thrombosis Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Online Distribution Channel, Hospital Pharmacies and Retail Pharmacies for the Years 2014, 2024 & 2030
    • TABLE 143: Rest of Europe Recent Past, Current & Future Analysis for Thrombosis Drugs by Drug Class - Anticoagulants, Antiplatelet Drugs and Thrombolytic Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 144: Rest of Europe Historic Review for Thrombosis Drugs by Drug Class - Anticoagulants, Antiplatelet Drugs and Thrombolytic Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 145: Rest of Europe 16-Year Perspective for Thrombosis Drugs by Drug Class - Percentage Breakdown of Value Sales for Anticoagulants, Antiplatelet Drugs and Thrombolytic Drugs for the Years 2014, 2024 & 2030
  • ASIA-PACIFIC
    • Thrombosis Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
    • TABLE 146: Asia-Pacific Recent Past, Current & Future Analysis for Thrombosis Drugs by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 147: Asia-Pacific Historic Review for Thrombosis Drugs by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 148: Asia-Pacific 16-Year Perspective for Thrombosis Drugs by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2024 & 2030
    • TABLE 149: Asia-Pacific Recent Past, Current & Future Analysis for Thrombosis Drugs by Disease Type - Venous Thromboembolism, Deep Vein Thrombosis, Pulmonary Embolism and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 150: Asia-Pacific Historic Review for Thrombosis Drugs by Disease Type - Venous Thromboembolism, Deep Vein Thrombosis, Pulmonary Embolism and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 151: Asia-Pacific 16-Year Perspective for Thrombosis Drugs by Disease Type - Percentage Breakdown of Value Sales for Venous Thromboembolism, Deep Vein Thrombosis, Pulmonary Embolism and Other Disease Types for the Years 2014, 2024 & 2030
    • TABLE 152: Asia-Pacific Recent Past, Current & Future Analysis for Thrombosis Drugs by Distribution Channel - Online Distribution Channel, Hospital Pharmacies and Retail Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 153: Asia-Pacific Historic Review for Thrombosis Drugs by Distribution Channel - Online Distribution Channel, Hospital Pharmacies and Retail Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 154: Asia-Pacific 16-Year Perspective for Thrombosis Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Online Distribution Channel, Hospital Pharmacies and Retail Pharmacies for the Years 2014, 2024 & 2030
    • TABLE 155: Asia-Pacific Recent Past, Current & Future Analysis for Thrombosis Drugs by Drug Class - Anticoagulants, Antiplatelet Drugs and Thrombolytic Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 156: Asia-Pacific Historic Review for Thrombosis Drugs by Drug Class - Anticoagulants, Antiplatelet Drugs and Thrombolytic Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 157: Asia-Pacific 16-Year Perspective for Thrombosis Drugs by Drug Class - Percentage Breakdown of Value Sales for Anticoagulants, Antiplatelet Drugs and Thrombolytic Drugs for the Years 2014, 2024 & 2030
  • AUSTRALIA
    • Thrombosis Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2024 (E)
    • TABLE 158: Australia Recent Past, Current & Future Analysis for Thrombosis Drugs by Disease Type - Venous Thromboembolism, Deep Vein Thrombosis, Pulmonary Embolism and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 159: Australia Historic Review for Thrombosis Drugs by Disease Type - Venous Thromboembolism, Deep Vein Thrombosis, Pulmonary Embolism and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 160: Australia 16-Year Perspective for Thrombosis Drugs by Disease Type - Percentage Breakdown of Value Sales for Venous Thromboembolism, Deep Vein Thrombosis, Pulmonary Embolism and Other Disease Types for the Years 2014, 2024 & 2030
    • TABLE 161: Australia Recent Past, Current & Future Analysis for Thrombosis Drugs by Distribution Channel - Online Distribution Channel, Hospital Pharmacies and Retail Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 162: Australia Historic Review for Thrombosis Drugs by Distribution Channel - Online Distribution Channel, Hospital Pharmacies and Retail Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 163: Australia 16-Year Perspective for Thrombosis Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Online Distribution Channel, Hospital Pharmacies and Retail Pharmacies for the Years 2014, 2024 & 2030
    • TABLE 164: Australia Recent Past, Current & Future Analysis for Thrombosis Drugs by Drug Class - Anticoagulants, Antiplatelet Drugs and Thrombolytic Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 165: Australia Historic Review for Thrombosis Drugs by Drug Class - Anticoagulants, Antiplatelet Drugs and Thrombolytic Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 166: Australia 16-Year Perspective for Thrombosis Drugs by Drug Class - Percentage Breakdown of Value Sales for Anticoagulants, Antiplatelet Drugs and Thrombolytic Drugs for the Years 2014, 2024 & 2030
  • INDIA
    • Thrombosis Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2024 (E)
    • TABLE 167: India Recent Past, Current & Future Analysis for Thrombosis Drugs by Disease Type - Venous Thromboembolism, Deep Vein Thrombosis, Pulmonary Embolism and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 168: India Historic Review for Thrombosis Drugs by Disease Type - Venous Thromboembolism, Deep Vein Thrombosis, Pulmonary Embolism and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 169: India 16-Year Perspective for Thrombosis Drugs by Disease Type - Percentage Breakdown of Value Sales for Venous Thromboembolism, Deep Vein Thrombosis, Pulmonary Embolism and Other Disease Types for the Years 2014, 2024 & 2030
    • TABLE 170: India Recent Past, Current & Future Analysis for Thrombosis Drugs by Distribution Channel - Online Distribution Channel, Hospital Pharmacies and Retail Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 171: India Historic Review for Thrombosis Drugs by Distribution Channel - Online Distribution Channel, Hospital Pharmacies and Retail Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 172: India 16-Year Perspective for Thrombosis Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Online Distribution Channel, Hospital Pharmacies and Retail Pharmacies for the Years 2014, 2024 & 2030
    • TABLE 173: India Recent Past, Current & Future Analysis for Thrombosis Drugs by Drug Class - Anticoagulants, Antiplatelet Drugs and Thrombolytic Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 174: India Historic Review for Thrombosis Drugs by Drug Class - Anticoagulants, Antiplatelet Drugs and Thrombolytic Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 175: India 16-Year Perspective for Thrombosis Drugs by Drug Class - Percentage Breakdown of Value Sales for Anticoagulants, Antiplatelet Drugs and Thrombolytic Drugs for the Years 2014, 2024 & 2030
  • SOUTH KOREA
    • TABLE 176: South Korea Recent Past, Current & Future Analysis for Thrombosis Drugs by Disease Type - Venous Thromboembolism, Deep Vein Thrombosis, Pulmonary Embolism and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 177: South Korea Historic Review for Thrombosis Drugs by Disease Type - Venous Thromboembolism, Deep Vein Thrombosis, Pulmonary Embolism and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 178: South Korea 16-Year Perspective for Thrombosis Drugs by Disease Type - Percentage Breakdown of Value Sales for Venous Thromboembolism, Deep Vein Thrombosis, Pulmonary Embolism and Other Disease Types for the Years 2014, 2024 & 2030
    • TABLE 179: South Korea Recent Past, Current & Future Analysis for Thrombosis Drugs by Distribution Channel - Online Distribution Channel, Hospital Pharmacies and Retail Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 180: South Korea Historic Review for Thrombosis Drugs by Distribution Channel - Online Distribution Channel, Hospital Pharmacies and Retail Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 181: South Korea 16-Year Perspective for Thrombosis Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Online Distribution Channel, Hospital Pharmacies and Retail Pharmacies for the Years 2014, 2024 & 2030
    • TABLE 182: South Korea Recent Past, Current & Future Analysis for Thrombosis Drugs by Drug Class - Anticoagulants, Antiplatelet Drugs and Thrombolytic Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 183: South Korea Historic Review for Thrombosis Drugs by Drug Class - Anticoagulants, Antiplatelet Drugs and Thrombolytic Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 184: South Korea 16-Year Perspective for Thrombosis Drugs by Drug Class - Percentage Breakdown of Value Sales for Anticoagulants, Antiplatelet Drugs and Thrombolytic Drugs for the Years 2014, 2024 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 185: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Thrombosis Drugs by Disease Type - Venous Thromboembolism, Deep Vein Thrombosis, Pulmonary Embolism and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 186: Rest of Asia-Pacific Historic Review for Thrombosis Drugs by Disease Type - Venous Thromboembolism, Deep Vein Thrombosis, Pulmonary Embolism and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 187: Rest of Asia-Pacific 16-Year Perspective for Thrombosis Drugs by Disease Type - Percentage Breakdown of Value Sales for Venous Thromboembolism, Deep Vein Thrombosis, Pulmonary Embolism and Other Disease Types for the Years 2014, 2024 & 2030
    • TABLE 188: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Thrombosis Drugs by Distribution Channel - Online Distribution Channel, Hospital Pharmacies and Retail Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 189: Rest of Asia-Pacific Historic Review for Thrombosis Drugs by Distribution Channel - Online Distribution Channel, Hospital Pharmacies and Retail Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 190: Rest of Asia-Pacific 16-Year Perspective for Thrombosis Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Online Distribution Channel, Hospital Pharmacies and Retail Pharmacies for the Years 2014, 2024 & 2030
    • TABLE 191: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Thrombosis Drugs by Drug Class - Anticoagulants, Antiplatelet Drugs and Thrombolytic Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 192: Rest of Asia-Pacific Historic Review for Thrombosis Drugs by Drug Class - Anticoagulants, Antiplatelet Drugs and Thrombolytic Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 193: Rest of Asia-Pacific 16-Year Perspective for Thrombosis Drugs by Drug Class - Percentage Breakdown of Value Sales for Anticoagulants, Antiplatelet Drugs and Thrombolytic Drugs for the Years 2014, 2024 & 2030
  • LATIN AMERICA
    • Thrombosis Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2024 (E)
    • TABLE 194: Latin America Recent Past, Current & Future Analysis for Thrombosis Drugs by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 195: Latin America Historic Review for Thrombosis Drugs by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 196: Latin America 16-Year Perspective for Thrombosis Drugs by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2024 & 2030
    • TABLE 197: Latin America Recent Past, Current & Future Analysis for Thrombosis Drugs by Disease Type - Venous Thromboembolism, Deep Vein Thrombosis, Pulmonary Embolism and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 198: Latin America Historic Review for Thrombosis Drugs by Disease Type - Venous Thromboembolism, Deep Vein Thrombosis, Pulmonary Embolism and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 199: Latin America 16-Year Perspective for Thrombosis Drugs by Disease Type - Percentage Breakdown of Value Sales for Venous Thromboembolism, Deep Vein Thrombosis, Pulmonary Embolism and Other Disease Types for the Years 2014, 2024 & 2030
    • TABLE 200: Latin America Recent Past, Current & Future Analysis for Thrombosis Drugs by Distribution Channel - Online Distribution Channel, Hospital Pharmacies and Retail Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 201: Latin America Historic Review for Thrombosis Drugs by Distribution Channel - Online Distribution Channel, Hospital Pharmacies and Retail Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 202: Latin America 16-Year Perspective for Thrombosis Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Online Distribution Channel, Hospital Pharmacies and Retail Pharmacies for the Years 2014, 2024 & 2030
    • TABLE 203: Latin America Recent Past, Current & Future Analysis for Thrombosis Drugs by Drug Class - Anticoagulants, Antiplatelet Drugs and Thrombolytic Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 204: Latin America Historic Review for Thrombosis Drugs by Drug Class - Anticoagulants, Antiplatelet Drugs and Thrombolytic Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 205: Latin America 16-Year Perspective for Thrombosis Drugs by Drug Class - Percentage Breakdown of Value Sales for Anticoagulants, Antiplatelet Drugs and Thrombolytic Drugs for the Years 2014, 2024 & 2030
  • ARGENTINA
    • TABLE 206: Argentina Recent Past, Current & Future Analysis for Thrombosis Drugs by Disease Type - Venous Thromboembolism, Deep Vein Thrombosis, Pulmonary Embolism and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 207: Argentina Historic Review for Thrombosis Drugs by Disease Type - Venous Thromboembolism, Deep Vein Thrombosis, Pulmonary Embolism and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 208: Argentina 16-Year Perspective for Thrombosis Drugs by Disease Type - Percentage Breakdown of Value Sales for Venous Thromboembolism, Deep Vein Thrombosis, Pulmonary Embolism and Other Disease Types for the Years 2014, 2024 & 2030
    • TABLE 209: Argentina Recent Past, Current & Future Analysis for Thrombosis Drugs by Distribution Channel - Online Distribution Channel, Hospital Pharmacies and Retail Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 210: Argentina Historic Review for Thrombosis Drugs by Distribution Channel - Online Distribution Channel, Hospital Pharmacies and Retail Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 211: Argentina 16-Year Perspective for Thrombosis Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Online Distribution Channel, Hospital Pharmacies and Retail Pharmacies for the Years 2014, 2024 & 2030
    • TABLE 212: Argentina Recent Past, Current & Future Analysis for Thrombosis Drugs by Drug Class - Anticoagulants, Antiplatelet Drugs and Thrombolytic Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 213: Argentina Historic Review for Thrombosis Drugs by Drug Class - Anticoagulants, Antiplatelet Drugs and Thrombolytic Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 214: Argentina 16-Year Perspective for Thrombosis Drugs by Drug Class - Percentage Breakdown of Value Sales for Anticoagulants, Antiplatelet Drugs and Thrombolytic Drugs for the Years 2014, 2024 & 2030
  • BRAZIL
    • TABLE 215: Brazil Recent Past, Current & Future Analysis for Thrombosis Drugs by Disease Type - Venous Thromboembolism, Deep Vein Thrombosis, Pulmonary Embolism and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 216: Brazil Historic Review for Thrombosis Drugs by Disease Type - Venous Thromboembolism, Deep Vein Thrombosis, Pulmonary Embolism and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 217: Brazil 16-Year Perspective for Thrombosis Drugs by Disease Type - Percentage Breakdown of Value Sales for Venous Thromboembolism, Deep Vein Thrombosis, Pulmonary Embolism and Other Disease Types for the Years 2014, 2024 & 2030
    • TABLE 218: Brazil Recent Past, Current & Future Analysis for Thrombosis Drugs by Distribution Channel - Online Distribution Channel, Hospital Pharmacies and Retail Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 219: Brazil Historic Review for Thrombosis Drugs by Distribution Channel - Online Distribution Channel, Hospital Pharmacies and Retail Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 220: Brazil 16-Year Perspective for Thrombosis Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Online Distribution Channel, Hospital Pharmacies and Retail Pharmacies for the Years 2014, 2024 & 2030
    • TABLE 221: Brazil Recent Past, Current & Future Analysis for Thrombosis Drugs by Drug Class - Anticoagulants, Antiplatelet Drugs and Thrombolytic Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 222: Brazil Historic Review for Thrombosis Drugs by Drug Class - Anticoagulants, Antiplatelet Drugs and Thrombolytic Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 223: Brazil 16-Year Perspective for Thrombosis Drugs by Drug Class - Percentage Breakdown of Value Sales for Anticoagulants, Antiplatelet Drugs and Thrombolytic Drugs for the Years 2014, 2024 & 2030
  • MEXICO
    • TABLE 224: Mexico Recent Past, Current & Future Analysis for Thrombosis Drugs by Disease Type - Venous Thromboembolism, Deep Vein Thrombosis, Pulmonary Embolism and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 225: Mexico Historic Review for Thrombosis Drugs by Disease Type - Venous Thromboembolism, Deep Vein Thrombosis, Pulmonary Embolism and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 226: Mexico 16-Year Perspective for Thrombosis Drugs by Disease Type - Percentage Breakdown of Value Sales for Venous Thromboembolism, Deep Vein Thrombosis, Pulmonary Embolism and Other Disease Types for the Years 2014, 2024 & 2030
    • TABLE 227: Mexico Recent Past, Current & Future Analysis for Thrombosis Drugs by Distribution Channel - Online Distribution Channel, Hospital Pharmacies and Retail Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 228: Mexico Historic Review for Thrombosis Drugs by Distribution Channel - Online Distribution Channel, Hospital Pharmacies and Retail Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 229: Mexico 16-Year Perspective for Thrombosis Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Online Distribution Channel, Hospital Pharmacies and Retail Pharmacies for the Years 2014, 2024 & 2030
    • TABLE 230: Mexico Recent Past, Current & Future Analysis for Thrombosis Drugs by Drug Class - Anticoagulants, Antiplatelet Drugs and Thrombolytic Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 231: Mexico Historic Review for Thrombosis Drugs by Drug Class - Anticoagulants, Antiplatelet Drugs and Thrombolytic Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 232: Mexico 16-Year Perspective for Thrombosis Drugs by Drug Class - Percentage Breakdown of Value Sales for Anticoagulants, Antiplatelet Drugs and Thrombolytic Drugs for the Years 2014, 2024 & 2030
  • REST OF LATIN AMERICA
    • TABLE 233: Rest of Latin America Recent Past, Current & Future Analysis for Thrombosis Drugs by Disease Type - Venous Thromboembolism, Deep Vein Thrombosis, Pulmonary Embolism and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 234: Rest of Latin America Historic Review for Thrombosis Drugs by Disease Type - Venous Thromboembolism, Deep Vein Thrombosis, Pulmonary Embolism and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 235: Rest of Latin America 16-Year Perspective for Thrombosis Drugs by Disease Type - Percentage Breakdown of Value Sales for Venous Thromboembolism, Deep Vein Thrombosis, Pulmonary Embolism and Other Disease Types for the Years 2014, 2024 & 2030
    • TABLE 236: Rest of Latin America Recent Past, Current & Future Analysis for Thrombosis Drugs by Distribution Channel - Online Distribution Channel, Hospital Pharmacies and Retail Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 237: Rest of Latin America Historic Review for Thrombosis Drugs by Distribution Channel - Online Distribution Channel, Hospital Pharmacies and Retail Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 238: Rest of Latin America 16-Year Perspective for Thrombosis Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Online Distribution Channel, Hospital Pharmacies and Retail Pharmacies for the Years 2014, 2024 & 2030
    • TABLE 239: Rest of Latin America Recent Past, Current & Future Analysis for Thrombosis Drugs by Drug Class - Anticoagulants, Antiplatelet Drugs and Thrombolytic Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 240: Rest of Latin America Historic Review for Thrombosis Drugs by Drug Class - Anticoagulants, Antiplatelet Drugs and Thrombolytic Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 241: Rest of Latin America 16-Year Perspective for Thrombosis Drugs by Drug Class - Percentage Breakdown of Value Sales for Anticoagulants, Antiplatelet Drugs and Thrombolytic Drugs for the Years 2014, 2024 & 2030
  • MIDDLE EAST
    • Thrombosis Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2024 (E)
    • TABLE 242: Middle East Recent Past, Current & Future Analysis for Thrombosis Drugs by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 243: Middle East Historic Review for Thrombosis Drugs by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 244: Middle East 16-Year Perspective for Thrombosis Drugs by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2024 & 2030
    • TABLE 245: Middle East Recent Past, Current & Future Analysis for Thrombosis Drugs by Disease Type - Venous Thromboembolism, Deep Vein Thrombosis, Pulmonary Embolism and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 246: Middle East Historic Review for Thrombosis Drugs by Disease Type - Venous Thromboembolism, Deep Vein Thrombosis, Pulmonary Embolism and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 247: Middle East 16-Year Perspective for Thrombosis Drugs by Disease Type - Percentage Breakdown of Value Sales for Venous Thromboembolism, Deep Vein Thrombosis, Pulmonary Embolism and Other Disease Types for the Years 2014, 2024 & 2030
    • TABLE 248: Middle East Recent Past, Current & Future Analysis for Thrombosis Drugs by Distribution Channel - Online Distribution Channel, Hospital Pharmacies and Retail Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 249: Middle East Historic Review for Thrombosis Drugs by Distribution Channel - Online Distribution Channel, Hospital Pharmacies and Retail Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 250: Middle East 16-Year Perspective for Thrombosis Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Online Distribution Channel, Hospital Pharmacies and Retail Pharmacies for the Years 2014, 2024 & 2030
    • TABLE 251: Middle East Recent Past, Current & Future Analysis for Thrombosis Drugs by Drug Class - Anticoagulants, Antiplatelet Drugs and Thrombolytic Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 252: Middle East Historic Review for Thrombosis Drugs by Drug Class - Anticoagulants, Antiplatelet Drugs and Thrombolytic Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 253: Middle East 16-Year Perspective for Thrombosis Drugs by Drug Class - Percentage Breakdown of Value Sales for Anticoagulants, Antiplatelet Drugs and Thrombolytic Drugs for the Years 2014, 2024 & 2030
  • IRAN
    • TABLE 254: Iran Recent Past, Current & Future Analysis for Thrombosis Drugs by Disease Type - Venous Thromboembolism, Deep Vein Thrombosis, Pulmonary Embolism and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 255: Iran Historic Review for Thrombosis Drugs by Disease Type - Venous Thromboembolism, Deep Vein Thrombosis, Pulmonary Embolism and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 256: Iran 16-Year Perspective for Thrombosis Drugs by Disease Type - Percentage Breakdown of Value Sales for Venous Thromboembolism, Deep Vein Thrombosis, Pulmonary Embolism and Other Disease Types for the Years 2014, 2024 & 2030
    • TABLE 257: Iran Recent Past, Current & Future Analysis for Thrombosis Drugs by Distribution Channel - Online Distribution Channel, Hospital Pharmacies and Retail Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 258: Iran Historic Review for Thrombosis Drugs by Distribution Channel - Online Distribution Channel, Hospital Pharmacies and Retail Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 259: Iran 16-Year Perspective for Thrombosis Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Online Distribution Channel, Hospital Pharmacies and Retail Pharmacies for the Years 2014, 2024 & 2030
    • TABLE 260: Iran Recent Past, Current & Future Analysis for Thrombosis Drugs by Drug Class - Anticoagulants, Antiplatelet Drugs and Thrombolytic Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 261: Iran Historic Review for Thrombosis Drugs by Drug Class - Anticoagulants, Antiplatelet Drugs and Thrombolytic Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 262: Iran 16-Year Perspective for Thrombosis Drugs by Drug Class - Percentage Breakdown of Value Sales for Anticoagulants, Antiplatelet Drugs and Thrombolytic Drugs for the Years 2014, 2024 & 2030
  • ISRAEL
    • TABLE 263: Israel Recent Past, Current & Future Analysis for Thrombosis Drugs by Disease Type - Venous Thromboembolism, Deep Vein Thrombosis, Pulmonary Embolism and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 264: Israel Historic Review for Thrombosis Drugs by Disease Type - Venous Thromboembolism, Deep Vein Thrombosis, Pulmonary Embolism and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 265: Israel 16-Year Perspective for Thrombosis Drugs by Disease Type - Percentage Breakdown of Value Sales for Venous Thromboembolism, Deep Vein Thrombosis, Pulmonary Embolism and Other Disease Types for the Years 2014, 2024 & 2030
    • TABLE 266: Israel Recent Past, Current & Future Analysis for Thrombosis Drugs by Distribution Channel - Online Distribution Channel, Hospital Pharmacies and Retail Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 267: Israel Historic Review for Thrombosis Drugs by Distribution Channel - Online Distribution Channel, Hospital Pharmacies and Retail Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 268: Israel 16-Year Perspective for Thrombosis Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Online Distribution Channel, Hospital Pharmacies and Retail Pharmacies for the Years 2014, 2024 & 2030
    • TABLE 269: Israel Recent Past, Current & Future Analysis for Thrombosis Drugs by Drug Class - Anticoagulants, Antiplatelet Drugs and Thrombolytic Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 270: Israel Historic Review for Thrombosis Drugs by Drug Class - Anticoagulants, Antiplatelet Drugs and Thrombolytic Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 271: Israel 16-Year Perspective for Thrombosis Drugs by Drug Class - Percentage Breakdown of Value Sales for Anticoagulants, Antiplatelet Drugs and Thrombolytic Drugs for the Years 2014, 2024 & 2030
  • SAUDI ARABIA
    • TABLE 272: Saudi Arabia Recent Past, Current & Future Analysis for Thrombosis Drugs by Disease Type - Venous Thromboembolism, Deep Vein Thrombosis, Pulmonary Embolism and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 273: Saudi Arabia Historic Review for Thrombosis Drugs by Disease Type - Venous Thromboembolism, Deep Vein Thrombosis, Pulmonary Embolism and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 274: Saudi Arabia 16-Year Perspective for Thrombosis Drugs by Disease Type - Percentage Breakdown of Value Sales for Venous Thromboembolism, Deep Vein Thrombosis, Pulmonary Embolism and Other Disease Types for the Years 2014, 2024 & 2030
    • TABLE 275: Saudi Arabia Recent Past, Current & Future Analysis for Thrombosis Drugs by Distribution Channel - Online Distribution Channel, Hospital Pharmacies and Retail Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 276: Saudi Arabia Historic Review for Thrombosis Drugs by Distribution Channel - Online Distribution Channel, Hospital Pharmacies and Retail Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 277: Saudi Arabia 16-Year Perspective for Thrombosis Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Online Distribution Channel, Hospital Pharmacies and Retail Pharmacies for the Years 2014, 2024 & 2030
    • TABLE 278: Saudi Arabia Recent Past, Current & Future Analysis for Thrombosis Drugs by Drug Class - Anticoagulants, Antiplatelet Drugs and Thrombolytic Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 279: Saudi Arabia Historic Review for Thrombosis Drugs by Drug Class - Anticoagulants, Antiplatelet Drugs and Thrombolytic Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 280: Saudi Arabia 16-Year Perspective for Thrombosis Drugs by Drug Class - Percentage Breakdown of Value Sales for Anticoagulants, Antiplatelet Drugs and Thrombolytic Drugs for the Years 2014, 2024 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 281: UAE Recent Past, Current & Future Analysis for Thrombosis Drugs by Disease Type - Venous Thromboembolism, Deep Vein Thrombosis, Pulmonary Embolism and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 282: UAE Historic Review for Thrombosis Drugs by Disease Type - Venous Thromboembolism, Deep Vein Thrombosis, Pulmonary Embolism and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 283: UAE 16-Year Perspective for Thrombosis Drugs by Disease Type - Percentage Breakdown of Value Sales for Venous Thromboembolism, Deep Vein Thrombosis, Pulmonary Embolism and Other Disease Types for the Years 2014, 2024 & 2030
    • TABLE 284: UAE Recent Past, Current & Future Analysis for Thrombosis Drugs by Distribution Channel - Online Distribution Channel, Hospital Pharmacies and Retail Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 285: UAE Historic Review for Thrombosis Drugs by Distribution Channel - Online Distribution Channel, Hospital Pharmacies and Retail Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 286: UAE 16-Year Perspective for Thrombosis Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Online Distribution Channel, Hospital Pharmacies and Retail Pharmacies for the Years 2014, 2024 & 2030
    • TABLE 287: UAE Recent Past, Current & Future Analysis for Thrombosis Drugs by Drug Class - Anticoagulants, Antiplatelet Drugs and Thrombolytic Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 288: UAE Historic Review for Thrombosis Drugs by Drug Class - Anticoagulants, Antiplatelet Drugs and Thrombolytic Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 289: UAE 16-Year Perspective for Thrombosis Drugs by Drug Class - Percentage Breakdown of Value Sales for Anticoagulants, Antiplatelet Drugs and Thrombolytic Drugs for the Years 2014, 2024 & 2030
  • REST OF MIDDLE EAST
    • TABLE 290: Rest of Middle East Recent Past, Current & Future Analysis for Thrombosis Drugs by Disease Type - Venous Thromboembolism, Deep Vein Thrombosis, Pulmonary Embolism and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 291: Rest of Middle East Historic Review for Thrombosis Drugs by Disease Type - Venous Thromboembolism, Deep Vein Thrombosis, Pulmonary Embolism and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 292: Rest of Middle East 16-Year Perspective for Thrombosis Drugs by Disease Type - Percentage Breakdown of Value Sales for Venous Thromboembolism, Deep Vein Thrombosis, Pulmonary Embolism and Other Disease Types for the Years 2014, 2024 & 2030
    • TABLE 293: Rest of Middle East Recent Past, Current & Future Analysis for Thrombosis Drugs by Distribution Channel - Online Distribution Channel, Hospital Pharmacies and Retail Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 294: Rest of Middle East Historic Review for Thrombosis Drugs by Distribution Channel - Online Distribution Channel, Hospital Pharmacies and Retail Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 295: Rest of Middle East 16-Year Perspective for Thrombosis Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Online Distribution Channel, Hospital Pharmacies and Retail Pharmacies for the Years 2014, 2024 & 2030
    • TABLE 296: Rest of Middle East Recent Past, Current & Future Analysis for Thrombosis Drugs by Drug Class - Anticoagulants, Antiplatelet Drugs and Thrombolytic Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 297: Rest of Middle East Historic Review for Thrombosis Drugs by Drug Class - Anticoagulants, Antiplatelet Drugs and Thrombolytic Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 298: Rest of Middle East 16-Year Perspective for Thrombosis Drugs by Drug Class - Percentage Breakdown of Value Sales for Anticoagulants, Antiplatelet Drugs and Thrombolytic Drugs for the Years 2014, 2024 & 2030
  • AFRICA
    • Thrombosis Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2024 (E)
    • TABLE 299: Africa Recent Past, Current & Future Analysis for Thrombosis Drugs by Disease Type - Venous Thromboembolism, Deep Vein Thrombosis, Pulmonary Embolism and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 300: Africa Historic Review for Thrombosis Drugs by Disease Type - Venous Thromboembolism, Deep Vein Thrombosis, Pulmonary Embolism and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 301: Africa 16-Year Perspective for Thrombosis Drugs by Disease Type - Percentage Breakdown of Value Sales for Venous Thromboembolism, Deep Vein Thrombosis, Pulmonary Embolism and Other Disease Types for the Years 2014, 2024 & 2030
    • TABLE 302: Africa Recent Past, Current & Future Analysis for Thrombosis Drugs by Distribution Channel - Online Distribution Channel, Hospital Pharmacies and Retail Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 303: Africa Historic Review for Thrombosis Drugs by Distribution Channel - Online Distribution Channel, Hospital Pharmacies and Retail Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 304: Africa 16-Year Perspective for Thrombosis Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Online Distribution Channel, Hospital Pharmacies and Retail Pharmacies for the Years 2014, 2024 & 2030
    • TABLE 305: Africa Recent Past, Current & Future Analysis for Thrombosis Drugs by Drug Class - Anticoagulants, Antiplatelet Drugs and Thrombolytic Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 306: Africa Historic Review for Thrombosis Drugs by Drug Class - Anticoagulants, Antiplatelet Drugs and Thrombolytic Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 307: Africa 16-Year Perspective for Thrombosis Drugs by Drug Class - Percentage Breakdown of Value Sales for Anticoagulants, Antiplatelet Drugs and Thrombolytic Drugs for the Years 2014, 2024 & 2030

IV. COMPETITION

Show more
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Contact Us +1-866-353-3335
Hi, how can we help?
Contact us!